Political Interference Prompted Pazdur Retirement: Peter Pitts
A former senior FDA official says the abrupt resignation of newly appointed CDER director Richard Pazdur — one of the nation’s most influential cancer-drug regulators — signals deepening political interference inside the agency and could trigger further staff departures. In an interview with NewsNation, Peter Pitts, a former FDA associate commissioner, said Pazdur’s decision to step down less than a month after being elevated to lead the agency’s drugs center followed a breakdown of trust between Pazdur and FDA commissioner Marty Makary.
Pazdur, widely regarded as the driving force behind two decades of accelerated advances in cancer drug approvals, had initially resisted taking the top drug-review job, Pitts said. According to Pitts, Makary personally visited Pazdur and urged him to accept the role, promising him full autonomy over CDER operations. “That turned out to be a complete load of you know what,” Pitts said during the interview.
Pitts said he learned from internal sources that shortly after appointing Pazdur, Makary informed him that two political appointees would be installed in key positions directly beneath him, despite Pazdur being assured he would control staffing decisions. Pazdur, a career regulator known for avoiding political fights, viewed the move as a breach of trust, Pitts said.
“Having his boss, who’s a political appointee, tell him that political guys are going to be put underneath him without any say-so is not the way to run a drug regulatory agency,” Pitts said. “It sends a very bad signal that politics rather than public health and science are going to rule the day.”
Pitts warned that Pazdur’s exit could have far-reaching consequences. He called Pazdur “a hero” who single-handedly reshaped U.S. cancer care and said losing him is “a loss for American health care, and especially for patients with cancer.” He also predicted more resignations could follow if FDA scientists believe political appointees are being allowed to override scientific judgment.
Meanwhile, Pazdur’s retirement prompted swift concern from biotech companies, patient groups, policy watchers and analysts worried about continued leadership turnover and regulatory uncertainty. Biotechnology Innovation Organization CEO John Crowley said his departure “raises serious concerns about the repeated turnover in key leadership occurring at the FDA. We need organizational strength and stability at the agency. This constant turmoil is undermining America's leadership in biotechnology, creating unprecedented regulatory instability and unpredictability, and risks ceding this critical sector to China.”
Wall Street analysts were quick to flag potential market and development impacts. RBC’s analysts and other market commentators warned Pazdur’s exit would “feed perceptions around internal turmoil at the FDA” and could be “a net negative for most of the sector,” citing increased uncertainty about approval pathways and leadership direction. Several investment notes emphasized the risk that another leadership vacuum could slow reviews or change priorities at CDER.
FDA has acknowledged Pazdur’s intent to retire and lauded his long record in oncology and regulatory innovation, while not offering detailed reasons for the timing. Agency officials and outside observers say the immediate questions are who will lead CDER next, whether Pazdur will change his mind during the retirement notice period, and how quickly the agency can restore a sense of continuity.